Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
The aim of the project is to demonstrate superior detection ratio of \[18F\]AlF-FAPI-74 PET/CT compared to \[18F\]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma (clinical T1-4N0-3M0) and pancreatic ductal adenocarcinoma (clinical T1-4N0-2M0-1) and describe the clinical utility of \[18F\]AlF-FAPI-74 PET/CT in oncological patients with a clinically challenging situation.
• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
• Age 18 or older.
• New histologic or cytologic proven diagnosis of oesophagogastric adenocarcinoma.
• Patient underwent a \[18F\]FDG PET/CT.
• TNM classification: cT1-4N0-3M0
• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
• Age 18 or older.
• New histologic or cytologic proven diagnosis of pancreatic ductal adenocarcinoma.
• Patient underwent a \[18F\]FDG PET/CT or conventional staging with CT or MRI.
• TNM classification: cT1-4N0-2M0-1, with the exception of upfront resectable patients.
• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
• Age 18 or older.
• Histologic or cytologic proven diagnosis of a malignancy.
• Patient underwent a \[18F\]FDG PET/CT.
• Unexplained symptoms, complaints, biochemical or imaging (scintigraphy, PET, CT, MR) findings.